4 Issues To Watch After 340B Orphan Drug Ruling

Law360, New York (October 15, 2015, 8:28 PM EDT) -- A court decision curtailing orphan drug discounts in the 340B program will likely prompt a minor exodus of health care providers from the program, invite other legal challenges to the program’s controversial policies, and ramp up pressure on Congress to intervene, attorneys say.

Here are four issues to watch in the aftermath.

Lost Discounts May Prompt Departures

The ruling from U.S. District Judge Rudolph Contreras on Wednesday dealt with an Affordable Care Act provision that bars certain providers from receiving 340B discounts for so-called orphan drugs that treat rare diseases.

The U.S. Department of Health and Human Services had argued that discounts...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!